Trastuzumab  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
treatment  ||| S:20 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
HER2-positive  ||| S:33 E:47 ||| CD
metastatic  ||| S:47 E:58 ||| JJ
adenocarcinoma  ||| S:58 E:73 ||| NN
of  ||| S:73 E:76 ||| IN
the  ||| S:76 E:80 ||| DT
stomach  ||| S:80 E:88 ||| NN
or  ||| S:88 E:91 ||| CC
gastro-oesophageal  ||| S:91 E:110 ||| JJ
junction  ||| S:110 E:119 ||| NNS
This  ||| S:119 E:124 ||| DT
paper  ||| S:124 E:130 ||| NN
presents  ||| S:130 E:139 ||| VBZ
a  ||| S:139 E:141 ||| DT
summary  ||| S:141 E:149 ||| NN
of  ||| S:149 E:152 ||| IN
the  ||| S:152 E:156 ||| DT
evidence  ||| S:156 E:165 ||| NN
review  ||| S:165 E:172 ||| NN
group  ||| S:172 E:178 ||| NN
( ||| S:178 E:179 ||| -LRB-
ERG ||| S:179 E:182 ||| NNP
)  ||| S:182 E:184 ||| -RRB-
report  ||| S:184 E:191 ||| NN
into  ||| S:191 E:196 ||| IN
trastuzumab  ||| S:196 E:208 ||| NN
for  ||| S:208 E:212 ||| IN
the  ||| S:212 E:216 ||| DT
treatment  ||| S:216 E:226 ||| NN
of  ||| S:226 E:229 ||| IN
human  ||| S:229 E:235 ||| JJ
epidermal  ||| S:235 E:245 ||| JJ
growth  ||| S:245 E:252 ||| NN
factor  ||| S:252 E:259 ||| NN
receptor  ||| S:259 E:268 ||| NN
2  ||| S:268 E:270 ||| CD
( ||| S:270 E:271 ||| -LRB-
HER2 ||| S:271 E:275 ||| NNP
) ||| S:275 E:276 ||| -RRB-
-positive  ||| S:276 E:286 ||| JJ
metastatic  ||| S:286 E:297 ||| JJ
adenocarcinoma  ||| S:297 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
the  ||| S:315 E:319 ||| DT
stomach  ||| S:319 E:327 ||| NN
( ||| S:327 E:328 ||| -LRB-
mGC ||| S:328 E:331 ||| NNP
)  ||| S:331 E:333 ||| -RRB-
or  ||| S:333 E:336 ||| CC
gastro-oesophageal  ||| S:336 E:355 ||| JJ
junction ||| S:355 E:363 ||| NN
.  ||| S:363 E:365 ||| .
HER2  ||| S:365 E:370 ||| NNP
positivity  ||| S:370 E:381 ||| NN
is  ||| S:381 E:384 ||| VBZ
defined  ||| S:384 E:392 ||| VBN
by  ||| S:392 E:395 ||| IN
immunohistochemistry  ||| S:395 E:416 ||| NNS
( ||| S:416 E:417 ||| -LRB-
IHC ||| S:417 E:420 ||| NNP
) ||| S:420 E:421 ||| -RRB-
3+  ||| S:421 E:424 ||| NNP
or  ||| S:424 E:427 ||| CC
IHC2+ ||| S:427 E:432 ||| FW
/ ||| S:432 E:433 ||| FW
fluorescence  ||| S:433 E:446 ||| FW
in  ||| S:446 E:449 ||| FW
situ  ||| S:449 E:454 ||| FW
hybridisation  ||| S:454 E:468 ||| FW
( ||| S:468 E:469 ||| -LRB-
FISH ||| S:469 E:473 ||| NNP
) ||| S:473 E:474 ||| -RRB-
+ ||| S:474 E:475 ||| NNP
.  ||| S:475 E:477 ||| .
The  ||| S:477 E:481 ||| DT
decision  ||| S:481 E:490 ||| NN
problem  ||| S:490 E:498 ||| NN
addressed  ||| S:498 E:508 ||| NNS
was  ||| S:508 E:512 ||| VBD
the  ||| S:512 E:516 ||| DT
testing  ||| S:516 E:524 ||| NN
of  ||| S:524 E:527 ||| IN
the  ||| S:527 E:531 ||| DT
whole  ||| S:531 E:537 ||| JJ
mGC  ||| S:537 E:541 ||| JJ
population  ||| S:541 E:552 ||| NN
with  ||| S:552 E:557 ||| IN
IHC  ||| S:557 E:561 ||| NNP
and ||| S:561 E:564 ||| CC
,  ||| S:564 E:566 ||| ,
for  ||| S:566 E:570 ||| IN
IHC2+  ||| S:570 E:576 ||| CD
patients ||| S:576 E:584 ||| NNS
,  ||| S:584 E:586 ||| ,
also  ||| S:586 E:591 ||| RB
with  ||| S:591 E:596 ||| IN
FISH ||| S:596 E:600 ||| NNP
,  ||| S:600 E:602 ||| ,
followed  ||| S:602 E:611 ||| VBN
by  ||| S:611 E:614 ||| IN
treatment  ||| S:614 E:624 ||| NN
of  ||| S:624 E:627 ||| IN
HER2-positive  ||| S:627 E:641 ||| CD
patients  ||| S:641 E:650 ||| NNS
with  ||| S:650 E:655 ||| IN
trastuzumab  ||| S:655 E:667 ||| VBG
combined  ||| S:667 E:676 ||| VBN
with  ||| S:676 E:681 ||| IN
cisplatin  ||| S:681 E:691 ||| NN
and  ||| S:691 E:695 ||| CC
either  ||| S:695 E:702 ||| DT
capecitabine  ||| S:702 E:715 ||| NN
or  ||| S:715 E:718 ||| CC
5-fluorouracil  ||| S:718 E:733 ||| NN
( ||| S:733 E:734 ||| -LRB-
5-FU ||| S:734 E:738 ||| NNP
)  ||| S:738 E:740 ||| -RRB-
[ ||| S:740 E:741 ||| -LRB-
HCX  ||| S:741 E:745 ||| NNP
( ||| S:745 E:746 ||| -LRB-
trastuzumab ||| S:746 E:757 ||| UH
,  ||| S:757 E:759 ||| ,
cisplatin ||| S:759 E:768 ||| NN
,  ||| S:768 E:770 ||| ,
capecitabine ||| S:770 E:782 ||| CD
) ||| S:782 E:783 ||| -RRB-
/ ||| S:783 E:784 ||| FW
fluorouracil  ||| S:784 E:797 ||| FW
( ||| S:797 E:798 ||| -LRB-
F ||| S:798 E:799 ||| NNP
) ||| S:799 E:800 ||| -RRB-
]  ||| S:800 E:802 ||| -RRB-
compared  ||| S:802 E:811 ||| VBN
with  ||| S:811 E:816 ||| IN
current  ||| S:816 E:824 ||| JJ
standard  ||| S:824 E:833 ||| JJ
NHS  ||| S:833 E:837 ||| NNP
therapy ||| S:837 E:844 ||| NN
.  ||| S:844 E:846 ||| .
The  ||| S:846 E:850 ||| DT
manufacturer ||| S:850 E:862 ||| NN
's  ||| S:862 E:865 ||| POS
submission  ||| S:865 E:876 ||| NN
contained  ||| S:876 E:886 ||| VBD
direct  ||| S:886 E:893 ||| JJ
evidence  ||| S:893 E:902 ||| NN
from  ||| S:902 E:907 ||| IN
the  ||| S:907 E:911 ||| DT
ToGA  ||| S:911 E:916 ||| JJ
trial ||| S:916 E:921 ||| NN
,  ||| S:921 E:923 ||| ,
a  ||| S:923 E:925 ||| DT
well-conducted ||| S:925 E:939 ||| JJ
,  ||| S:939 E:941 ||| ,
multinational ||| S:941 E:954 ||| JJ
,  ||| S:954 E:956 ||| ,
phase  ||| S:956 E:962 ||| NN
III  ||| S:962 E:966 ||| NNP
randomised  ||| S:966 E:977 ||| VBD
controlled  ||| S:977 E:988 ||| VBN
trial  ||| S:988 E:994 ||| NN
( ||| S:994 E:995 ||| -LRB-
RCT ||| S:995 E:998 ||| NNP
)  ||| S:998 E:1000 ||| -RRB-
that  ||| S:1000 E:1005 ||| IN
compared  ||| S:1005 E:1014 ||| VBN
HCX ||| S:1014 E:1017 ||| NNP
/ ||| S:1017 E:1018 ||| NNP
F  ||| S:1018 E:1020 ||| NN
with  ||| S:1020 E:1025 ||| IN
cisplatin  ||| S:1025 E:1035 ||| NN
and  ||| S:1035 E:1039 ||| CC
a  ||| S:1039 E:1041 ||| DT
fluoropyrimidine  ||| S:1041 E:1058 ||| NN
alone  ||| S:1058 E:1064 ||| RB
[ ||| S:1064 E:1065 ||| -LRB-
cisplatin ||| S:1065 E:1074 ||| UH
,  ||| S:1074 E:1076 ||| ,
capecitabine  ||| S:1076 E:1089 ||| NNS
( ||| S:1089 E:1090 ||| -LRB-
CX ||| S:1090 E:1092 ||| NNP
) ||| S:1092 E:1093 ||| -RRB-
/ ||| S:1093 E:1094 ||| NNP
F ||| S:1094 E:1095 ||| NNP
] ||| S:1095 E:1096 ||| -RRB-
.  ||| S:1096 E:1098 ||| .
HCX ||| S:1098 E:1101 ||| NNP
/ ||| S:1101 E:1102 ||| NNP
F  ||| S:1102 E:1104 ||| NNP
showed  ||| S:1104 E:1111 ||| VBD
statistically  ||| S:1111 E:1125 ||| RB
significantly  ||| S:1125 E:1139 ||| RB
better  ||| S:1139 E:1146 ||| RBR
overall  ||| S:1146 E:1154 ||| JJ
survival  ||| S:1154 E:1163 ||| NN
in  ||| S:1163 E:1166 ||| IN
the  ||| S:1166 E:1170 ||| DT
European  ||| S:1170 E:1179 ||| JJ
Medicines  ||| S:1179 E:1189 ||| JJ
Agency-licensed  ||| S:1189 E:1205 ||| JJ
population  ||| S:1205 E:1216 ||| NN
subgroup  ||| S:1216 E:1225 ||| NNS
( ||| S:1225 E:1226 ||| -LRB-
74 ||| S:1226 E:1228 ||| CD
% ||| S:1228 E:1229 ||| NN
)  ||| S:1229 E:1231 ||| -RRB-
( ||| S:1231 E:1232 ||| -LRB-
hazard  ||| S:1232 E:1239 ||| NN
ratio  ||| S:1239 E:1245 ||| NN
0.65 ||| S:1245 E:1249 ||| CD
,  ||| S:1249 E:1251 ||| ,
95 ||| S:1251 E:1253 ||| CD
%  ||| S:1253 E:1255 ||| NN
confidence  ||| S:1255 E:1266 ||| NN
interval  ||| S:1266 E:1275 ||| VBD
0.51  ||| S:1275 E:1280 ||| CD
to  ||| S:1280 E:1283 ||| TO
0.83 ||| S:1283 E:1287 ||| CD
) ||| S:1287 E:1288 ||| -RRB-
,  ||| S:1288 E:1290 ||| ,
corresponding  ||| S:1290 E:1304 ||| JJ
to  ||| S:1304 E:1307 ||| TO
median  ||| S:1307 E:1314 ||| JJ
survival  ||| S:1314 E:1323 ||| NN
of  ||| S:1323 E:1326 ||| IN
16  ||| S:1326 E:1329 ||| CD
months  ||| S:1329 E:1336 ||| NNS
versus  ||| S:1336 E:1343 ||| IN
11.8  ||| S:1343 E:1348 ||| CD
months ||| S:1348 E:1354 ||| NNS
.  ||| S:1354 E:1356 ||| .
No  ||| S:1356 E:1359 ||| DT
other  ||| S:1359 E:1365 ||| JJ
evidence  ||| S:1365 E:1374 ||| NN
exists  ||| S:1374 E:1381 ||| VBZ
for  ||| S:1381 E:1385 ||| IN
the  ||| S:1385 E:1389 ||| DT
efficacy  ||| S:1389 E:1398 ||| NN
of  ||| S:1398 E:1401 ||| IN
any  ||| S:1401 E:1405 ||| DT
therapy  ||| S:1405 E:1413 ||| NN
in  ||| S:1413 E:1416 ||| IN
a  ||| S:1416 E:1418 ||| DT
known  ||| S:1418 E:1424 ||| VBN
HER2-positive  ||| S:1424 E:1438 ||| CD
mGC  ||| S:1438 E:1442 ||| JJ
population ||| S:1442 E:1452 ||| NN
;  ||| S:1452 E:1454 ||| :
other  ||| S:1454 E:1460 ||| JJ
comparisons  ||| S:1460 E:1472 ||| NNS
extrapolate  ||| S:1472 E:1484 ||| VBN
from  ||| S:1484 E:1489 ||| IN
trials  ||| S:1489 E:1496 ||| NNS
in  ||| S:1496 E:1499 ||| IN
mixed  ||| S:1499 E:1505 ||| JJ
HER2  ||| S:1505 E:1510 ||| CD
status  ||| S:1510 E:1517 ||| NN
populations ||| S:1517 E:1528 ||| NNS
.  ||| S:1528 E:1530 ||| .
The  ||| S:1530 E:1534 ||| DT
ERG  ||| S:1534 E:1538 ||| NNP
accepted  ||| S:1538 E:1547 ||| VBD
the  ||| S:1547 E:1551 ||| DT
manufacturer ||| S:1551 E:1563 ||| NN
's  ||| S:1563 E:1566 ||| POS
view  ||| S:1566 E:1571 ||| NN
that  ||| S:1571 E:1576 ||| IN
a  ||| S:1576 E:1578 ||| DT
meaningful  ||| S:1578 E:1589 ||| JJ
network  ||| S:1589 E:1597 ||| NN
meta-analysis  ||| S:1597 E:1611 ||| NN
to  ||| S:1611 E:1614 ||| TO
establish  ||| S:1614 E:1624 ||| VB
a  ||| S:1624 E:1626 ||| DT
comparison  ||| S:1626 E:1637 ||| NN
for  ||| S:1637 E:1641 ||| IN
HCX ||| S:1641 E:1644 ||| NNP
/ ||| S:1644 E:1645 ||| NNP
F  ||| S:1645 E:1647 ||| NN
compared  ||| S:1647 E:1656 ||| VBN
with  ||| S:1656 E:1661 ||| IN
current  ||| S:1661 E:1669 ||| JJ
standard  ||| S:1669 E:1678 ||| JJ
NHS  ||| S:1678 E:1682 ||| NNP
therapy  ||| S:1682 E:1690 ||| NN
[ ||| S:1690 E:1691 ||| -LRB-
epirubicin ||| S:1691 E:1701 ||| UH
,  ||| S:1701 E:1703 ||| ,
cisplatin ||| S:1703 E:1712 ||| NN
,  ||| S:1712 E:1714 ||| ,
capecitabine  ||| S:1714 E:1727 ||| NNS
( ||| S:1727 E:1728 ||| -LRB-
ECX ||| S:1728 E:1731 ||| NNP
) ||| S:1731 E:1732 ||| -RRB-
/ ||| S:1732 E:1733 ||| CD
epirubicin ||| S:1733 E:1743 ||| NN
,  ||| S:1743 E:1745 ||| ,
oxaliplatin ||| S:1745 E:1756 ||| NN
,  ||| S:1756 E:1758 ||| ,
capecitabine  ||| S:1758 E:1771 ||| NNS
( ||| S:1771 E:1772 ||| -LRB-
EOX ||| S:1772 E:1775 ||| NNP
) ||| S:1775 E:1776 ||| -RRB-
/ ||| S:1776 E:1777 ||| CD
epirubicin ||| S:1777 E:1787 ||| NN
,  ||| S:1787 E:1789 ||| ,
cisplatin ||| S:1789 E:1798 ||| NN
,  ||| S:1798 E:1800 ||| ,
5-FU  ||| S:1800 E:1805 ||| NNP
( ||| S:1805 E:1806 ||| -LRB-
ECF ||| S:1806 E:1809 ||| NNP
) ||| S:1809 E:1810 ||| -RRB-
]  ||| S:1810 E:1812 ||| -RRB-
was  ||| S:1812 E:1816 ||| VBD
not  ||| S:1816 E:1820 ||| RB
possible ||| S:1820 E:1828 ||| JJ
,  ||| S:1828 E:1830 ||| ,
but  ||| S:1830 E:1834 ||| CC
was  ||| S:1834 E:1838 ||| VBD
unconvinced  ||| S:1838 E:1850 ||| VBN
by  ||| S:1850 E:1853 ||| IN
arguments  ||| S:1853 E:1863 ||| NNS
advanced  ||| S:1863 E:1872 ||| VBD
in  ||| S:1872 E:1875 ||| IN
the  ||| S:1875 E:1879 ||| DT
alternative  ||| S:1879 E:1891 ||| JJ
narrative  ||| S:1891 E:1901 ||| NN
synthesis ||| S:1901 E:1910 ||| NN
.  ||| S:1910 E:1912 ||| .
These  ||| S:1912 E:1918 ||| DT
involved  ||| S:1918 E:1927 ||| JJ
disregarding  ||| S:1927 E:1940 ||| JJ
evidence  ||| S:1940 E:1949 ||| NN
from  ||| S:1949 E:1954 ||| IN
a  ||| S:1954 E:1956 ||| DT
meta-analysis  ||| S:1956 E:1970 ||| JJ
and  ||| S:1970 E:1974 ||| CC
interpreting  ||| S:1974 E:1987 ||| VBG
non-significant  ||| S:1987 E:2003 ||| JJ
results  ||| S:2003 E:2011 ||| NNS
of  ||| S:2011 E:2014 ||| IN
small  ||| S:2014 E:2020 ||| JJ
RCTs  ||| S:2020 E:2025 ||| JJ
comparing  ||| S:2025 E:2035 ||| JJ
epirubicin-containing  ||| S:2035 E:2057 ||| JJ
triplets  ||| S:2057 E:2066 ||| NN
with  ||| S:2066 E:2071 ||| IN
cisplatin ||| S:2071 E:2080 ||| NN
,  ||| S:2080 E:2082 ||| ,
5-FU  ||| S:2082 E:2087 ||| NNP
( ||| S:2087 E:2088 ||| -LRB-
CF ||| S:2088 E:2090 ||| NNP
) ||| S:2090 E:2091 ||| -RRB-
/ ||| S:2091 E:2092 ||| FW
capecitabine  ||| S:2092 E:2105 ||| FW
( ||| S:2105 E:2106 ||| -LRB-
X ||| S:2106 E:2107 ||| NNP
)  ||| S:2107 E:2109 ||| -RRB-
doublets  ||| S:2109 E:2118 ||| NN
as  ||| S:2118 E:2121 ||| IN
evidence  ||| S:2121 E:2130 ||| NN
of  ||| S:2130 E:2133 ||| IN
no  ||| S:2133 E:2136 ||| DT
difference  ||| S:2136 E:2147 ||| NN
between  ||| S:2147 E:2155 ||| IN
triplet  ||| S:2155 E:2163 ||| NN
and  ||| S:2163 E:2167 ||| CC
doublet  ||| S:2167 E:2175 ||| JJ
regimens ||| S:2175 E:2183 ||| NN
.  ||| S:2183 E:2185 ||| .
The  ||| S:2185 E:2189 ||| DT
high  ||| S:2189 E:2194 ||| JJ
CX ||| S:2194 E:2196 ||| NNP
/ ||| S:2196 E:2197 ||| NNP
F  ||| S:2197 E:2199 ||| NNP
dose  ||| S:2199 E:2204 ||| NN
in  ||| S:2204 E:2207 ||| IN
the  ||| S:2207 E:2211 ||| DT
ToGA  ||| S:2211 E:2216 ||| JJ
trial  ||| S:2216 E:2222 ||| NN
was  ||| S:2222 E:2226 ||| VBD
an  ||| S:2226 E:2229 ||| DT
additional  ||| S:2229 E:2240 ||| JJ
basis  ||| S:2240 E:2246 ||| NN
for  ||| S:2246 E:2250 ||| IN
the  ||| S:2250 E:2254 ||| DT
contention  ||| S:2254 E:2265 ||| NN
of  ||| S:2265 E:2268 ||| IN
equivalence ||| S:2268 E:2279 ||| NN
.  ||| S:2279 E:2281 ||| .
An  ||| S:2281 E:2284 ||| DT
appropriate  ||| S:2284 E:2296 ||| JJ
de  ||| S:2296 E:2299 ||| FW
novo  ||| S:2299 E:2304 ||| FW
economic  ||| S:2304 E:2313 ||| JJ
evaluation ||| S:2313 E:2323 ||| NN
,  ||| S:2323 E:2325 ||| ,
including  ||| S:2325 E:2335 ||| VBG
an  ||| S:2335 E:2338 ||| DT
economic  ||| S:2338 E:2347 ||| JJ
model  ||| S:2347 E:2353 ||| NN
that  ||| S:2353 E:2358 ||| WDT
separately  ||| S:2358 E:2369 ||| RB
compared  ||| S:2369 E:2378 ||| VBN
HCX  ||| S:2378 E:2382 ||| NNP
or  ||| S:2382 E:2385 ||| CC
trastuzumab ||| S:2385 E:2396 ||| NN
,  ||| S:2396 E:2398 ||| ,
cisplatin ||| S:2398 E:2407 ||| NN
,  ||| S:2407 E:2409 ||| ,
5-FU  ||| S:2409 E:2414 ||| NNP
( ||| S:2414 E:2415 ||| -LRB-
HCF ||| S:2415 E:2418 ||| NNP
)  ||| S:2418 E:2420 ||| -RRB-
with  ||| S:2420 E:2425 ||| IN
the  ||| S:2425 E:2429 ||| DT
triplet  ||| S:2429 E:2437 ||| JJ
regimens  ||| S:2437 E:2446 ||| JJ
ECX ||| S:2446 E:2449 ||| NNP
,  ||| S:2449 E:2451 ||| ,
EOX  ||| S:2451 E:2455 ||| NNP
and  ||| S:2455 E:2459 ||| CC
ECF ||| S:2459 E:2462 ||| NNP
,  ||| S:2462 E:2464 ||| ,
based  ||| S:2464 E:2470 ||| VBN
on  ||| S:2470 E:2473 ||| IN
a  ||| S:2473 E:2475 ||| DT
simple ||| S:2475 E:2481 ||| JJ
,  ||| S:2481 E:2483 ||| ,
three-state  ||| S:2483 E:2495 ||| JJ
cohort  ||| S:2495 E:2502 ||| JJ
model  ||| S:2502 E:2508 ||| NN
( ||| S:2508 E:2509 ||| -LRB-
progression-free ||| S:2509 E:2525 ||| NNP
,  ||| S:2525 E:2527 ||| ,
disease ||| S:2527 E:2534 ||| NN
,  ||| S:2534 E:2536 ||| ,
progression  ||| S:2536 E:2548 ||| NN
and  ||| S:2548 E:2552 ||| CC
death ||| S:2552 E:2557 ||| NN
) ||| S:2557 E:2558 ||| -RRB-
,  ||| S:2558 E:2560 ||| ,
was  ||| S:2560 E:2564 ||| VBD
submitted ||| S:2564 E:2573 ||| VBN
.  ||| S:2573 E:2575 ||| .
Utility  ||| S:2575 E:2583 ||| NN
weights  ||| S:2583 E:2591 ||| NNS
were  ||| S:2591 E:2596 ||| VBD
applied  ||| S:2596 E:2604 ||| VBN
to  ||| S:2604 E:2607 ||| TO
estimate  ||| S:2607 E:2616 ||| VB
quality-adjusted  ||| S:2616 E:2633 ||| JJ
life-years  ||| S:2633 E:2644 ||| NN
( ||| S:2644 E:2645 ||| -LRB-
QALYs ||| S:2645 E:2650 ||| NNP
) ||| S:2650 E:2651 ||| -RRB-
.  ||| S:2651 E:2653 ||| .
Costs  ||| S:2653 E:2659 ||| NNS
were  ||| S:2659 E:2664 ||| VBD
assessed  ||| S:2664 E:2673 ||| VBN
from  ||| S:2673 E:2678 ||| IN
an  ||| S:2678 E:2681 ||| DT
NHS  ||| S:2681 E:2685 ||| NNP
perspective ||| S:2685 E:2696 ||| NN
,  ||| S:2696 E:2698 ||| ,
and  ||| S:2698 E:2702 ||| CC
incorporated  ||| S:2702 E:2715 ||| VBN
the  ||| S:2715 E:2719 ||| DT
acquisition  ||| S:2719 E:2731 ||| NN
and  ||| S:2731 E:2735 ||| CC
monitoring  ||| S:2735 E:2746 ||| VBG
costs  ||| S:2746 E:2752 ||| NNS
of  ||| S:2752 E:2755 ||| IN
the  ||| S:2755 E:2759 ||| DT
alternative  ||| S:2759 E:2771 ||| JJ
regimens ||| S:2771 E:2779 ||| NN
,  ||| S:2779 E:2781 ||| ,
HER2  ||| S:2781 E:2786 ||| CD
testing ||| S:2786 E:2793 ||| NN
,  ||| S:2793 E:2795 ||| ,
adverse  ||| S:2795 E:2803 ||| JJ
events  ||| S:2803 E:2810 ||| NNS
and  ||| S:2810 E:2814 ||| CC
other  ||| S:2814 E:2820 ||| JJ
supportive  ||| S:2820 E:2831 ||| JJ
care  ||| S:2831 E:2836 ||| NN
costs ||| S:2836 E:2841 ||| NNS
.  ||| S:2841 E:2843 ||| .
An  ||| S:2843 E:2846 ||| DT
8-year  ||| S:2846 E:2853 ||| JJ
time  ||| S:2853 E:2858 ||| NN
horizon  ||| S:2858 E:2866 ||| NN
was  ||| S:2866 E:2870 ||| VBD
used  ||| S:2870 E:2875 ||| VBN
to  ||| S:2875 E:2878 ||| TO
represent  ||| S:2878 E:2888 ||| VB
a  ||| S:2888 E:2890 ||| DT
lifetime  ||| S:2890 E:2899 ||| NN
analysis ||| S:2899 E:2907 ||| NN
.  ||| S:2907 E:2909 ||| .
Results  ||| S:2909 E:2917 ||| NNS
from  ||| S:2917 E:2922 ||| IN
the  ||| S:2922 E:2926 ||| DT
ToGA  ||| S:2926 E:2931 ||| JJ
trial  ||| S:2931 E:2937 ||| NN
were  ||| S:2937 E:2942 ||| VBD
combined  ||| S:2942 E:2951 ||| VBN
with  ||| S:2951 E:2956 ||| IN
a  ||| S:2956 E:2958 ||| DT
series  ||| S:2958 E:2965 ||| NN
of  ||| S:2965 E:2968 ||| IN
assumptions  ||| S:2968 E:2980 ||| NNS
on  ||| S:2980 E:2983 ||| IN
relative  ||| S:2983 E:2992 ||| JJ
treatment  ||| S:2992 E:3002 ||| NN
effects  ||| S:3002 E:3010 ||| NNS
and  ||| S:3010 E:3014 ||| CC
testing  ||| S:3014 E:3022 ||| NN
strategies ||| S:3022 E:3032 ||| NNS
.  ||| S:3032 E:3034 ||| .
The  ||| S:3034 E:3038 ||| DT
manufacturer ||| S:3038 E:3050 ||| NN
's  ||| S:3050 E:3053 ||| POS
results  ||| S:3053 E:3061 ||| NNS
produced  ||| S:3061 E:3070 ||| VBD
an  ||| S:3070 E:3073 ||| DT
incremental  ||| S:3073 E:3085 ||| JJ
cost-effectiveness  ||| S:3085 E:3104 ||| JJ
ratio  ||| S:3104 E:3110 ||| NN
( ||| S:3110 E:3111 ||| -LRB-
ICER ||| S:3111 E:3115 ||| NNP
)  ||| S:3115 E:3117 ||| -RRB-
of  ||| S:3117 E:3120 ||| IN
£  ||| S:3120 E:3122 ||| FW
53,010  ||| S:3122 E:3129 ||| FW
per  ||| S:3129 E:3133 ||| FW
QALY  ||| S:3133 E:3138 ||| FW
for  ||| S:3138 E:3142 ||| FW
HCX  ||| S:3142 E:3146 ||| FW
versus  ||| S:3146 E:3153 ||| FW
ECX ||| S:3153 E:3156 ||| FW
.  ||| S:3156 E:3158 ||| .
Although  ||| S:3158 E:3167 ||| IN
the  ||| S:3167 E:3171 ||| DT
manufacturer  ||| S:3171 E:3184 ||| NN
undertook  ||| S:3184 E:3194 ||| VBD
a  ||| S:3194 E:3196 ||| DT
detailed  ||| S:3196 E:3205 ||| JJ
set  ||| S:3205 E:3209 ||| NN
of  ||| S:3209 E:3212 ||| IN
sensitivity  ||| S:3212 E:3224 ||| JJ
analyses ||| S:3224 E:3232 ||| NNS
,  ||| S:3232 E:3234 ||| ,
several  ||| S:3234 E:3242 ||| JJ
alternative  ||| S:3242 E:3254 ||| NN
model  ||| S:3254 E:3260 ||| NN
assumptions  ||| S:3260 E:3272 ||| NNS
were  ||| S:3272 E:3277 ||| VBD
not  ||| S:3277 E:3281 ||| RB
evaluated ||| S:3281 E:3290 ||| VBN
.  ||| S:3290 E:3292 ||| .
The  ||| S:3292 E:3296 ||| DT
ERG  ||| S:3296 E:3300 ||| NNP
undertook  ||| S:3300 E:3310 ||| VBD
a  ||| S:3310 E:3312 ||| DT
series  ||| S:3312 E:3319 ||| NN
of  ||| S:3319 E:3322 ||| IN
alternative  ||| S:3322 E:3334 ||| JJ
base-case  ||| S:3334 E:3344 ||| JJ
analyses ||| S:3344 E:3352 ||| NNS
.  ||| S:3352 E:3354 ||| .
As  ||| S:3354 E:3357 ||| IN
a  ||| S:3357 E:3359 ||| DT
result  ||| S:3359 E:3366 ||| NN
of  ||| S:3366 E:3369 ||| IN
these  ||| S:3369 E:3375 ||| DT
analyses ||| S:3375 E:3383 ||| NN
,  ||| S:3383 E:3385 ||| ,
EOX  ||| S:3385 E:3389 ||| NNP
replaced  ||| S:3389 E:3398 ||| VBD
ECX  ||| S:3398 E:3402 ||| NNP
as  ||| S:3402 E:3405 ||| IN
the  ||| S:3405 E:3409 ||| DT
appropriate  ||| S:3409 E:3421 ||| JJ
comparator ||| S:3421 E:3431 ||| NN
,  ||| S:3431 E:3433 ||| ,
and  ||| S:3433 E:3437 ||| CC
the  ||| S:3437 E:3441 ||| DT
ICER  ||| S:3441 E:3446 ||| NNP
for  ||| S:3446 E:3450 ||| IN
the  ||| S:3450 E:3454 ||| DT
comparison  ||| S:3454 E:3465 ||| NN
of  ||| S:3465 E:3468 ||| IN
HCX  ||| S:3468 E:3472 ||| NNP
vs  ||| S:3472 E:3475 ||| VBD
EOX  ||| S:3475 E:3479 ||| NNP
increased  ||| S:3479 E:3489 ||| VBD
to  ||| S:3489 E:3492 ||| TO
between  ||| S:3492 E:3500 ||| IN
£  ||| S:3500 E:3502 ||| NNP
66,982  ||| S:3502 E:3509 ||| NNP
and  ||| S:3509 E:3513 ||| CC
£  ||| S:3513 E:3515 ||| CD
71,636  ||| S:3515 E:3522 ||| CD
per  ||| S:3522 E:3526 ||| IN
QALY ||| S:3526 E:3530 ||| NNP
.  ||| S:3530 E:3532 ||| .
The  ||| S:3532 E:3536 ||| DT
impact  ||| S:3536 E:3543 ||| NN
of  ||| S:3543 E:3546 ||| IN
implementation  ||| S:3546 E:3561 ||| NN
of  ||| S:3561 E:3564 ||| IN
alternative  ||| S:3564 E:3576 ||| JJ
testing  ||| S:3576 E:3584 ||| NN
strategies  ||| S:3584 E:3595 ||| NNS
remained  ||| S:3595 E:3604 ||| VBD
unclear ||| S:3604 E:3611 ||| JJ
.  ||| S:3611 E:3613 ||| .
There  ||| S:3613 E:3619 ||| EX
is  ||| S:3619 E:3622 ||| VBZ
also  ||| S:3622 E:3627 ||| RB
considerable  ||| S:3627 E:3640 ||| JJ
uncertainty  ||| S:3640 E:3652 ||| NN
surrounding  ||| S:3652 E:3664 ||| VBG
the  ||| S:3664 E:3668 ||| DT
true  ||| S:3668 E:3673 ||| JJ
estimate  ||| S:3673 E:3682 ||| NN
of  ||| S:3682 E:3685 ||| IN
effectiveness  ||| S:3685 E:3699 ||| NN
for  ||| S:3699 E:3703 ||| IN
the  ||| S:3703 E:3707 ||| DT
comparison  ||| S:3707 E:3718 ||| NN
between  ||| S:3718 E:3726 ||| IN
triplet  ||| S:3726 E:3734 ||| FW
regimens  ||| S:3734 E:3743 ||| FW
containing  ||| S:3743 E:3754 ||| FW
epirubicin  ||| S:3754 E:3765 ||| FW
( ||| S:3765 E:3766 ||| -LRB-
ECX ||| S:3766 E:3769 ||| NNP
/ ||| S:3769 E:3770 ||| NNP
ECF ||| S:3770 E:3773 ||| NNP
/ ||| S:3773 E:3774 ||| NNP
EOX ||| S:3774 E:3777 ||| NNP
)  ||| S:3777 E:3779 ||| -RRB-
and  ||| S:3779 E:3783 ||| CC
doublet  ||| S:3783 E:3791 ||| JJ
CX ||| S:3791 E:3793 ||| NNP
/ ||| S:3793 E:3794 ||| NNP
F  ||| S:3794 E:3796 ||| NNP
regimens ||| S:3796 E:3804 ||| NN
.  ||| S:3804 E:3806 ||| .
Consequently ||| S:3806 E:3818 ||| RB
,  ||| S:3818 E:3820 ||| ,
the  ||| S:3820 E:3824 ||| DT
view  ||| S:3824 E:3829 ||| NN
of  ||| S:3829 E:3832 ||| IN
the  ||| S:3832 E:3836 ||| DT
ERG  ||| S:3836 E:3840 ||| NNP
was  ||| S:3840 E:3844 ||| VBD
that  ||| S:3844 E:3849 ||| IN
there  ||| S:3849 E:3855 ||| EX
is  ||| S:3855 E:3858 ||| VBZ
insufficient  ||| S:3858 E:3871 ||| JJ
evidence  ||| S:3871 E:3880 ||| NN
on  ||| S:3880 E:3883 ||| IN
the  ||| S:3883 E:3887 ||| DT
efficacy  ||| S:3887 E:3896 ||| NN
of  ||| S:3896 E:3899 ||| IN
HCX ||| S:3899 E:3902 ||| NNP
/ ||| S:3902 E:3903 ||| NNP
F  ||| S:3903 E:3905 ||| NN
compared  ||| S:3905 E:3914 ||| VBN
with  ||| S:3914 E:3919 ||| IN
current  ||| S:3919 E:3927 ||| JJ
NHS  ||| S:3927 E:3931 ||| NNP
standard  ||| S:3931 E:3940 ||| JJ
therapy  ||| S:3940 E:3948 ||| NN
for  ||| S:3948 E:3952 ||| IN
an  ||| S:3952 E:3955 ||| DT
ICER  ||| S:3955 E:3960 ||| NNP
to  ||| S:3960 E:3963 ||| TO
be  ||| S:3963 E:3966 ||| VB
determined  ||| S:3966 E:3977 ||| VBN
with  ||| S:3977 E:3982 ||| IN
any  ||| S:3982 E:3986 ||| DT
degree  ||| S:3986 E:3993 ||| NN
of  ||| S:3993 E:3996 ||| IN
certainty ||| S:3996 E:4005 ||| NN
.  ||| S:4005 E:4007 ||| .
